Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 99,346 shares of the medical equipment provider’s stock after selling 3,580 shares during the period. Peregrine Capital Management LLC’s holdings in Lantheus were worth $8,887,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Groupama Asset Managment acquired a new position in Lantheus in the third quarter valued at approximately $439,000. Swedbank AB boosted its stake in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after acquiring an additional 385,000 shares during the period. Janus Henderson Group PLC boosted its stake in Lantheus by 7.7% in the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after acquiring an additional 257,022 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in Lantheus in the third quarter valued at approximately $25,955,000. Finally, Point72 DIFC Ltd acquired a new position in Lantheus in the third quarter valued at approximately $23,001,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Trading Down 2.5 %

LNTH opened at $79.94 on Tuesday. Lantheus Holdings, Inc. has a twelve month low of $56.06 and a twelve month high of $126.89. The stock has a market cap of $5.56 billion, a PE ratio of 13.30 and a beta of 0.44. The business’s 50 day moving average is $91.17 and its 200-day moving average is $97.53.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.